Group 1 - The core point of the article highlights that four funds under Baoying Fund experienced a decline of over 9% in 2025, with specific funds managed by Yao Yi and Zhang Ruolun showing significant losses [1][2] - Baoying Advantage Industry Mixed C and A funds reported declines of 15.66% and 15.32% respectively, with Yao Yi managing these funds since March 2021 after a tenure at Huatai Securities [1][2] - The top ten holdings of Baoying Advantage Industry Mixed fund include companies such as Bai Li Tianheng, Heng Rui Pharmaceutical, and WuXi AppTec, indicating a focus on the pharmaceutical sector [1] Group 2 - Baoying Brand Consumption Stock C and A funds recorded declines of 9.87% and 9.11% respectively, managed by Zhang Ruolun since August 2025 [1][2] - The Baoying Brand Consumption fund maintains a diversified portfolio across major consumer sectors, with top holdings including Kweichow Moutai, Tencent Holdings, and Haidilao [1][2] - The funds have been operational since 2019, with the Brand Consumption funds focusing on sectors like liquor, home appliances, and leisure food [1][2]

Group 1 - In 2025, four funds under the management of Baoying Fund experienced a decline of over 9% [1] - The Baoying Advantage Industry Mixed C and A funds, managed by Yao Yi, fell by 15.66% and 15.32% respectively [1] - The top ten holdings of Baoying Advantage Industry Mixed fund include companies such as Bai Li Tian Heng, Heng Rui Pharmaceutical, and WuXi AppTec [1] Group 2 - The Baoying Brand Consumption Stock C and A funds, managed by Zhang Ruolun, declined by 9.87% and 9.11% respectively [2] - The Baoying Brand Consumption fund diversifies its holdings across various consumer sectors, including liquor, home appliances, and leisure food [1] - The top ten holdings of Baoying Brand Consumption fund include Kweichow Moutai, Tencent Holdings, and Haidilao [1]

Core Viewpoint - The Hang Seng Hong Kong Stock Connect Innovative Drug Index has seen a 0.3% increase, with significant gains in individual stocks, reflecting a positive trend in the innovative pharmaceutical sector driven by government policies and increasing demand for new drugs [1] Group 1: Market Performance - The Hang Seng Hong Kong Stock Connect Innovative Drug Index rose by 0.3% [1] - Notable stock performances include BGI Genomics rising over 7%, Tonghua Dongbao Pharmaceutical increasing over 4%, and Innovent Biologics up over 2% [1] - The trading volume for the Hong Kong Stock Connect Innovative Drug ETF, E Fund (159316), reached approximately 500 million yuan [1] Group 2: Government Policy - The "Guangzhou Plan for Accelerating the Construction of a Strong Advanced Manufacturing City (2024-2035)" was recently issued, emphasizing the acceleration of innovative drug strategic layout [1] - The plan focuses on the development of monoclonal antibodies, vaccines, blood products, and diagnostic reagents in the biopharmaceutical sector [1] - Other cities such as Beijing, Shanghai, Chongqing, and Xi'an have also introduced policies to promote high-quality development in the innovative drug industry [1] Group 3: Industry Outlook - Huachuang Securities believes that the pharmaceutical industry is reaching new heights due to the continuous demand for medical solutions and unmet needs [1] - Pharmaceutical companies are increasingly investing in research and development to meet these demands [1] - China has become a significant player in global innovative drug research and development, with a continuous rise in overseas licensing activity [1] - The industry is entering a revenue era driven by innovation [1] Group 4: Investment Opportunities - The Hang Seng Hong Kong Stock Connect Innovative Drug Index is the first index with a "purity" of 100% focused on innovative drugs, targeting leading companies in the Hong Kong stock market [1] - The E Fund (159316) is currently the only product tracking this index, providing investors with a streamlined way to capitalize on investment opportunities in this sector [1]

Core Viewpoint - The approval and clinical application of the new generation TRK inhibitor, Zolacotrine (Yinoxin, ICP-723), marks a significant breakthrough in China's broad-spectrum anti-cancer drug development, providing better treatment options for patients with NTRK fusion-positive solid tumors [1][3]. Group 1: Drug Development and Approval - Zolacotrine is the first domestically developed TRK inhibitor approved for clinical use in China, with prescriptions already issued in multiple hospitals [1][3]. - The drug addresses unmet clinical needs for patients with NTRK fusion-positive tumors, which are prevalent in over 26 types of solid tumors [4]. Group 2: Clinical Efficacy - Clinical studies show Zolacotrine has a total response rate (ORR) of 89.1%, with a disease control rate (DCR) of 96.4%, and a 24-month progression-free survival rate (PFS) of 77.4% [5]. - The drug demonstrates a total survival rate (OS) of 90.8%, indicating its potential to provide long-term relief for patients [5]. Group 3: Safety and Administration - Zolacotrine has a low rate of treatment-related adverse events leading to permanent discontinuation, at only 0.4%, enhancing patient compliance [7]. - The once-daily oral administration of Zolacotrine offers convenience for long-term treatment [7]. Group 4: Overcoming Resistance - Zolacotrine effectively overcomes resistance issues associated with first-generation TRK inhibitors, maintaining strong inhibitory activity against common mutations in the TRK kinase domain [9]. Group 5: CNS Penetration - The drug's unique molecular structure allows it to effectively penetrate the blood-brain barrier, achieving a 100% objective response rate in intracranial lesions, thus providing comprehensive protection for patients with brain metastases [10]. Group 6: Company Perspective - The CEO of the company expressed gratitude towards regulatory bodies, clinical experts, and partners for their support in the development and launch of Zolacotrine, emphasizing its role in improving the quality of life for cancer patients [12].

Group 1 - The core issue in cancer research is that some tumor cells can evade the immune system, making traditional immunotherapy ineffective [1] - A research team from Peking University has developed a protein-targeted degradation technology that forces hidden tumor cells to reveal themselves, providing a new approach to overcoming cancer immune tolerance [1] Group 2 - Relevant A-share concept stocks include Innovent Biologics and Hecolin Pharmaceutical [2]

Core Insights - The biopharmaceutical industry is at a significant historical juncture in 2025, marking the end of the "14th Five-Year Plan" and the beginning of the "15th Five-Year Plan," with a focus on balancing technological innovation and commercial rationality, as well as global and local strategies [1][6] - The company, Innovent Biologics, celebrates its 10th anniversary in 2025, achieving significant milestones including a record-breaking collaboration worth over $2 billion with Zenas and achieving profitability two years ahead of schedule [1][6] Company Achievements - Innovent Biologics has successfully launched two innovative drugs, including the first approved CD19 monoclonal antibody for diffuse large B-cell lymphoma (DLBCL) and the first domestically developed TRK inhibitor [7] - The company's core product, Obinutuzumab, has received approval for first-line treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and has been included in the national medical insurance, benefiting more patients [7] Research and Development Progress - The company has made breakthroughs in innovative drug development, with the first BCL2 inhibitor recognized as a breakthrough therapy in China, and multiple clinical trials for various indications are accelerating [8] - The company is advancing its ADC platform with the first ADC drug entering clinical stages, enhancing its competitiveness in solid tumors [8] Future Strategy - Innovent Biologics aims to leverage "Chinese originality" and "global vision" to embark on a new decade of growth, with plans to launch five to six innovative drugs and accelerate globalization efforts [9] - The company is committed to maintaining an entrepreneurial spirit and enhancing its overseas team capabilities to achieve global commercialization of three to four products [9]

Group 1 - The overall market sentiment for innovative drug overseas BD transactions has shifted from extreme optimism to a more rational understanding, leading to significant stock price declines for many small companies in the A-share and H-share markets [1] - The driving logic for the innovative drug industry in 2026 will rely on tangible overseas clinical advancements and increased certainty in overseas commercialization, moving away from transient BD transactions [1] - Major companies in the innovative drug sector, including industry leaders and quality second-tier companies, are beginning to stabilize and show upward trends in stock prices [1] Group 2 - Two significant oncology drugs, AK112 from Kangfang Biotech and SKB264 from Kelun-Biotech, are expected to have major impacts in their respective fields, with ongoing clinical trials and potential breakthroughs [3] - Kangfang Biotech's AK112 has seen a series of clinical advancements that have sparked global interest in second-generation IO development, leading to multiple impactful BD transactions [3] - SKB264 is positioned as a potential global first-in-class drug in the ADC category, with ongoing clinical trials and a significant focus on its efficacy in various cancers [5] Group 3 - Kangfang Biotech is expected to read out three major Phase III clinical results in 2026, including two first-line lung cancer trials, with potential approval timelines set for 2025 and 2027 [4] - Kelun-Biotech's SKB264 is anticipated to read out important clinical results for two major indications in 2026, which could validate its market potential outside of China [7] - The innovative drug industry is expected to see significant clinical progress from various companies that have engaged in substantial BD transactions in 2024-2025, enhancing the long-term value of their overseas projects [7][9]

Group 1 - The stock price of Nocera Biopharma (688428) closed at 21.65 yuan on January 7, 2026, with an increase of 3.49% and a turnover rate of 3.57% [1] - The trading volume was 95,800 shares, with a total transaction amount of 206 million yuan [1] - On January 7, the net outflow of funds from major investors was 1.24 million yuan, while retail investors saw a net inflow of 1.70 million yuan [2] Group 2 - As of December 31, 2025, the total share capital of Nocera Biopharma remains unchanged at 25 billion ordinary shares, with no change in the number of issued shares [2] - The number of shares listed on the Hong Kong Stock Exchange is 1,496,284,235, which includes 1,493,798,235 issued shares and 2,486,000 treasury shares [1][2] - The number of shares listed on the Sci-Tech Innovation Board is 268,359,717 [1][2] - The company has two equity incentive plans, with 4,531,250 shares remaining to be granted under the 2023 RMB stock incentive plan and 9,645,200 shares under the 2024 RMB stock incentive plan [1]

Core Viewpoint - As of December 31, 2025, the number of A-share shareholders for the company is expected to be approximately 18,100 [1] Summary by Relevant Categories Company Information - The company, 诺诚健华, has indicated that it anticipates having around 18,100 A-share shareholders by the end of 2025 [1]

Group 1 - The company, Nocera, stated that its pipeline advancement and commercialization expansion are progressing smoothly according to plans and targets, with normal operations [1] - The company's stock price in the secondary market is influenced by various factors, and investors are advised to be cautious about investment risks [1] - The company will decide whether to initiate a buyback based on its development status and the capital market environment [1]